Sha Huan-Huan, Wang Dan-Dan, Yan Da-Li, Hu Yong, Yang Su-Jin, Liu Si-Wen, Feng Ji-Feng
Department of Chemotherapy, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
Department of General Surgery, The First Clinical School of Nanjing Medical University, Nanjing 210009, China.
Biosci Rep. 2017 Jan 27;37(1). doi: 10.1042/BSR20160332. Print 2017 Feb 28.
Chimaeric antigen receptor (CAR) T-cell therapies, as one of the cancer immunotherapies, have heralded a new era of treating cancer. The accumulating data, especially about CAR-modified T cells against CD19 support that CAR T-cell therapy is a highly effective immune therapy for B-cell malignancies. Apart from CD19, there have been many trials of CAR T cells directed other tumour specific or associated antigens (TSAs/TAAs) in haematologic malignancies and solid tumours. This review will briefly summarize basic CAR structure, parts of reported TSAs/TAAs, results of the clinical trials of CAR T-cell therapies as well as two life-threatening side effects. Experiments in vivo or in vitro, ongoing clinical trials and the outlook for CAR T-cell therapies also be included. Our future efforts will focus on identification of more viable cancer targets and more strategies to make CAR T-cell therapy safer.
嵌合抗原受体（CAR）T细胞疗法作为癌症免疫疗法之一，开创了癌症治疗的新纪元。越来越多的数据，尤其是关于靶向CD19的CAR修饰T细胞的数据，支持CAR T细胞疗法是治疗B细胞恶性肿瘤的一种高效免疫疗法。除了CD19之外，针对血液系统恶性肿瘤和实体瘤中其他肿瘤特异性或相关抗原（TSAs/TAAs）的CAR T细胞已经进行了许多试验。本综述将简要总结CAR的基本结构、已报道的TSAs/TAAs、CAR T细胞疗法的临床试验结果以及两种危及生命的副作用。还将包括体内或体外实验、正在进行的临床试验以及CAR T细胞疗法的前景。我们未来的努力将集中在识别更多可行的癌症靶点以及使CAR T细胞疗法更安全的更多策略上。
